 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > A longitudinal prospective study of active tuberculosis in a Western Europe setting : |
(Universitat Autònoma de Barcelona) (Institut Germans Trias i Pujol) (Hospital Universitari Vall d'Hebron) (Institut Germans Trias i Pujol) (Institut Germans Trias i Pujol. Fundació Lluita Contra les Infeccions) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Hospital Universitari Vall d'Hebron) (Hospital Universitari Vall d'Hebron) (Hospital Universitari Vall d'Hebron) (Hospital Universitari Vall d'Hebron) (Institut de Recerca Sant Joan de Déu) (Serveis Clínics (Barcelona)) (Serveis Clínics (Barcelona)) (Universitat Autònoma de Barcelona) (Instituto de Salud Carlos III) (Instituto de Salud Carlos III) (Institut de Recerca Sant Pau) (Hospital Universitari Vall d'Hebron) (Universitat Autònoma de Barcelona)
| Data: | 2024 |
| Resum: | This study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution. People with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed. The study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months. IP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB. The online version contains supplementary material available at 10. 1007/s15010-024-02184-2. |
| Ajuts: | Instituto de Salud Carlos III PI20/01424 Instituto de Salud Carlos III PI22/00766 Ministerio de Sanidad y Consumo CB06/06/0031 European Commission 847762 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-500 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00920 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Mycobacterium tuberculosis ; Inflammatory parameters ; HRQoL ; Clinical monitoring ; Biomarkers |
| Publicat a: | Infection, Vol. 52 (february 2024) , p. 611-623, ISSN 1439-0973 |
